We are offering an exciting opportunity for a skilled Development Analyst seeking a challenging career in a Biotech company.
Development Analyst
read more
30 Technology
30 Technology completes final patient dosing in its TB study in South Africa
30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa.
30 Technology Holds Inaugural Scientific Advisory Board Meeting
We are delighted to announce the first meeting of 30 Technology’s newly formed Scientific Advisory Board (SAB) held in our offices in Central London.
30 Technology launches a critical clinical trial in patients with newly diagnosed tuberculosis
We are delighted to announce that our latest clinical trial ‘RESP30X-EBA’ is active and recruiting at the TASK Clinical Research Centre, South Africa.
30 Technology expands its clinical team
30 Technology has been actively engaged in expanding its clinical team to drive its lead respiratory assets through multiple ongoing early phase clinical trials.
30 Technology receives regulatory approval for TASK tuberculosis Study in South Africa
30 Technology is delighted to report that this month we received full regulatory approval to start our Phase 2 trial in adults with newly diagnosed pulmonary tuberculosis (TB).
30 Technology Expands Its Scientific Team And Opens New Innovation Hub At Scale Space, Imperial College London
30 Technology is delighted to announce the opening of its new Innovation Centre in Scale Space – a part of Imperial College London’s White City campus located in the heart of West London.
30 Technology’s Clinically Validated Antimicrobial Nitric Oxide Platform Acquired by Convatec Group Plc for Several Applications
Transaction total value up to £176 million
30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis
Thirty Technology joins the fight against antibiotic resistant infection.
30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections
RESP301 to combat antibiotic resistant/refractory infection in people with cystic fibrosis